Amgen Inc. AMGN, +0.03% was downgraded at BofA Securities, with analyst Geoff Meacham saying he believes the lingering COVID-19 headwinds and net pricing pressures that weighed on the biotechnology company in 2021 are likely to continue this year. Meacham cut his rating to neutral, after being at buy since March 2020, and lowered his stock price target to $255 from $285.